Financhill
Back

Vanda Pharmaceuticals Quote, Financials, Valuation and Earnings

Vanda Pharmaceuticals Price Quote

$5.11
+0.17 (+3.44%)
(Updated: November 22, 2024 at 5:55 PM ET)

Vanda Pharmaceuticals Key Stats

Sell
37
Vanda Pharmaceuticals (VNDA) is a Sell

Day range:
$4.83 - $4.94
52-week range:
$3.44 - $6.75
Dividend yield:
0%
P/E ratio:
123.50
P/S ratio:
1.50
P/B ratio:
0.53%

Volume:
344.2K
Avg. volume:
754.9K
1-year change:
43.19%
Market cap:
$288M
Revenue:
$192.6M
EPS:
$-0.28

How Much Does Vanda Pharmaceuticals Make?

Is Vanda Pharmaceuticals Growing As A Company?

  • What Is Vanda Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.23%
  • What Is Vanda Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Vanda Pharmaceuticals Stock Price Performance

What Is Vanda Pharmaceuticals 52-Week High & Low?

Vanda Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Vanda Pharmaceuticals?

Is Vanda Pharmaceuticals Cash Flow Positive?

  • What Is VNDA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$17.7M
  • What Is Vanda Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $0
  • What Is Vanda Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$65.2M

Vanda Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    VNDA return on invested capital is -3.02%
  • What Is Vanda Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -2.53%
  • What Is VNDA Return On Equity?
    ROE is a measure of profitability and is -3.02%

Vanda Pharmaceuticals Earnings Date & Stock Price

Vanda Pharmaceuticals Competitors

  • Who Are Vanda Pharmaceuticals's Competitors?
    Below is a list of companies who compete with Vanda Pharmaceuticals or are related in some way:
    • Black Diamond Therapeutics Inc (BDTX)
    • Edgewise Therapeutics Inc (EWTX)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Zevra Therapeutics Inc (ZVRA)

Vanda Pharmaceuticals Dividend Yield

Vanda Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 22.76% -3.06%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 10.43
Upside from Last Price: 111.08%

Major Shareholders

  • How many VNDA shares are owned by institutional investors?
    66.5M VNDA shares are owned by institutional investors
  • How many VNDA shares are owned by insiders?
    4M VNDA shares are owned by insiders